Under the leadership of PD Dr. Niklas Klümper, Assistant Physician at the Department of Urology at the University Hospital Bonn (UKB) and Clinician Scientist of the BMBF-funded ACCENT program and PD Dr. Markus Eckstein, senior physician at the Institute of Pathology at the Uniklinikum Erlangen of the Friedrich-Alexander-University Erlangen-Nürnberg (FAU), an interdisciplinary research team has published new findings that indicate which patients with advanced urothelial carcinoma could benefit in particular from the new targeted therapy with the antibody-drug conjugate enfortumab vedotin.

Related Keywords

Bonn , Nordrhein Westfalen , Germany , Markus Eckstein Uniklinikum Erlangen , Uniklinikum Erlangen , Markus Eckstein , Department Of Urology , University Hospital Bonn , Institute Of Pathology , Hospital Bonn , Assistant Physician , Clinician Scientist , Friedrich Alexander University Erlangen N , Clinical Oncology , Scarcinoma , Ntibody , Antibody Drug Conjugate , Biomarker , Dancer , Chemotherapy , Enomic , Hospital , Ncology , Pathology , Research , Humor , Virology ,